Subscription pricing
There have been no new cases of naturally occurring polio in North America in recent years. ███ █████ ███ █████████████ ██ ███ █████ ██ █████ ████ ████ ██ █████ ████████ ███ ██████ ██ ███ ████████ ████████████ ████ ████ █████ ███████ ██████ ████████████ ███████████ █████ ███████ █████ ███ ████ █████████ █████ █████████████ █████ ███ ███ ██████ ██ █████ ██ ██████████████████ █████ █████ ██ █████ ███████ ██ ██ ████ ██ ██████ ████ ███ ██ ███ ██ ███ ████ ████████ ████ █████ ███████ ███ █████ ████████ █████████
Summarize Argument
IPV should be the most commonly used polio vaccine for North American children, instead of OPV. OPV causes all new cases of polio each year in North America, and IPV would reduce the number of cases by half.
Notable Assumptions
The author assumes that IPV does not have serious side effects that make it undesirable for use on most children—side effects that may outweigh the benefit of decreasing the number of cases of live polio a year. Furthermore, the author assumes that there are no other significant undesirable consequences that could arise from the proposed switch.
19.
Which one of the following, ██ █████ ████ ███████ ███ █████████
a
If IPV replaces ███ ██ ███ ████ ████████ ████ █████ ████████ ██ █████ █ ███ ███ █████ ██ █████████ █████████ █████ ██ █████ ███████ ████ ██████ ████ █████
b
The vast majority ██ █████ ██ █████ ██████ ██ ███ ████ ████████ ██ ████████ ████ ███████████ ███ ███████████ ████████████████ ██████████
c
A child's risk ██ ███████████ █████ ████ ███ ███ ████ █████████ ██ █ ██ ███ ████████ █████ ██ █████████████ ████ ████ ███ ████ ██ █████ ██████ ██ ██████████
d
Although IPV is █████████ ██ ████ ████████ ████████ ████ █████████ ████ █████████████ █████ ████████████ ████████ ███ ████
e
IPV, like most █████████ ███████ █ ██████ ████ ██ ████████ ████████ ██ ████████ ████ ████████████ ████████ ████ ██ █████████